E N D
2. An Innovative Solution to the Old and Difficult Problem of Targeted Therapy
3. Superparamagnetic and single domain nanoparticles are active in a magnetic field, returning to a normal state when the field is removed, giving rise to the concept of a “biomagnetic switch”.
Under appropriately designed conditions, magnetically responsive nanoparticles (MNP) can be used to target therapeutics to a site or to drive the nanomechanical movement of tissue .
Magnetic vectoring employs a shaped external magnetic field to drive a desired physiological event.
4. The overall goal has been to get more drug to target tissue, especially tumors, with less to normal tissues: effectively raising the therapeutic index
12. Use of shaped external magnetic fields to cause biologically modified MNP to concentrate at a site, concurrent with cellular uptake.
The capacity to concentrate at a site concurrent with cellular uptake, offers potential for higher dose regimens with minimal harm to healthy tissue.
MNP size and configuration allows for internalization or endocytosis into target tissue, with internal release of therapeutic.
13. Developing a site-specific targeting mechanism based on the unique physical properties of nanoparticles.
Validating magnetic vectoring technology in a range of human healthcare applications, in collaborations with major research institutions.